The U.S. Food and Drug Administration announced on Monday that it will extend the review period for Capricor Therapeutics’ experimental cell therapy aimed at treating Duchenne muscular dystrophy. The agency set a new deadline of November 22, giving the company three more months to submit additional clinical data for its product, deramiocel.
Background on the therapy and the disease
Duchenne muscular dystrophy is a rare, progressive genetic disorder that primarily affects boys, leading to severe muscle wasting and loss of function. Capricor’s therapy, deramiocel, is designed to address the underlying muscle degeneration by delivering genetically modified cells that can help restore muscle tissue.
Recent regulatory history
Last month, an FDA advisory panel voted nine‑to‑three against the effectiveness data presented for deramiocel, a setback that raised concerns among investors and families awaiting a new treatment option. Following that vote, Capricor’s share price fell before rebounding sharply after the latest extension announcement, with the stock climbing more than 20 % in early trading.
Company response
Capricor CEO Linda Marbán said the additional time will allow the company to incorporate new follow‑up data from the HOPE‑3 study, which now provides one of the most extensive clinical datasets on upper‑limb function in Duchenne patients. “With an additional year of follow‑up from HOPE‑3, we now have one of the most extensive clinical datasets evaluating upper limb function in Duchenne,” Marbán stated.
What the extension means
The FDA’s decision does not constitute approval of the therapy; it simply extends the period for the agency to review the supplemental data that Capricor has submitted. If the additional data address the concerns raised by the advisory panel, the company could move closer to a potential approval, offering hope to families affected by this devastating disease.
Industry context
Cell‑based therapies for rare genetic disorders have been a growing focus for biotech firms, but the regulatory pathway remains rigorous. The FDA’s careful review process reflects both the promise of innovative treatments and the need to ensure safety and efficacy for patients.
Looking ahead
Capricor plans to continue its clinical development program while awaiting the FDA’s final decision. Families, clinicians, and investors will be watching the November deadline closely, as the outcome could shape the future of treatment options for Duchenne muscular dystrophy.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
